HEM Stock Overview
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Hemostemix Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.04 |
52 Week High | CA$0.17 |
52 Week Low | CA$0.035 |
Beta | 0.52 |
1 Month Change | -33.33% |
3 Month Change | -60.00% |
1 Year Change | -73.33% |
3 Year Change | -85.71% |
5 Year Change | -96.00% |
Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Shareholder Returns
HEM | CA Biotechs | CA Market | |
---|---|---|---|
7D | 0% | 3.5% | 3.1% |
1Y | -73.3% | -36.3% | 9.9% |
Return vs Industry: HEM underperformed the Canadian Biotechs industry which returned -34.7% over the past year.
Return vs Market: HEM underperformed the Canadian Market which returned 8.8% over the past year.
Price Volatility
HEM volatility | |
---|---|
HEM Average Weekly Movement | 20.0% |
Biotechs Industry Average Movement | 11.8% |
Market Average Movement | 8.7% |
10% most volatile stocks in CA Market | 17.7% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: HEM's share price has been volatile over the past 3 months.
Volatility Over Time: HEM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Thomas Smeenk | hemostemix.com |
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient’s own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Hemostemix Inc. Fundamentals Summary
HEM fundamental statistics | |
---|---|
Market cap | CA$3.48m |
Earnings (TTM) | -CA$2.50m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs HEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HEM income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$2.50m |
Earnings | -CA$2.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.029 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -58.6% |
How did HEM perform over the long term?
See historical performance and comparison